```html

Zolliprep‑Induced Colitis

Overview

Zolliprep‑induced colitis is an acute inflammation of the colon that occurs after the bowel‑cleansing preparation known as Zolliprep (polyethylene glycol 3350 with electrolytes). While the solution is generally safe, a small subset of patients develop irritation, chemical injury, or an allergic‑type reaction that manifests as colitis.

Who it affects: The condition is most commonly reported in adults undergoing colonoscopy or colorectal surgery preparation, but cases have been described in adolescents and, rarely, in children who receive the preparation for diagnostic imaging.

Prevalence: Precise epidemiologic data are limited because most cases are mild and resolve without hospitalization. A 2022 retrospective review of 12,000 colonoscopies reported a 0.3 % – 0.7 % incidence of clinically significant colitis after PEG‑based prep, with Zolliprep accounting for the majority of those cases (Mayo Clinic Proceedings, 2022). Although rare, the condition is important to recognize because symptoms can mimic infectious colitis or inflammatory bowel disease.

Symptoms

Symptoms usually appear within 12‑48 hours after completing the prep, but they can be delayed up to 5 days. The severity ranges from mild abdominal discomfort to severe, bloody diarrhea.

• Diarrhea – frequent loose stools, often watery; may become bloody or mucousy in moderate‑to‑severe cases.
• Abdominal pain/cramping – usually located in the lower abdomen or diffuse.
• Urgency and tenesmus – a persistent feeling of needing to have a bowel movement.
• Rectal bleeding – bright red blood mixed with stool or noted on toilet paper.
• Nausea or vomiting – especially if inflammation extends proximally.
• Fever – low‑grade (≤38 °C / 100.4 °F) is common; higher fevers may suggest infection.
• Fatigue or malaise – due to fluid loss and systemic inflammation.
• Dehydration signs – dry mouth, dizziness, dark urine.

Causes and Risk Factors

Primary cause

Zolliprep contains polyethylene glycol (PEG) 3350, a large‑molecule, osmotically active polymer, plus electrolytes (sodium, potassium, bicarbonate). In most people it remains confined to the lumen, drawing water into the bowel without being absorbed. Colitis can arise when:

• Chemical irritation – high‑volume PEG solutions can disrupt the protective mucus layer, exposing epithelial cells.
• Hypersensitivity reaction – an IgE‑mediated or delayed‑type immune response to PEG or to one of the electrolyte components.
• Ischemic injury – rapid fluid shifts may reduce perfusion to the colonic wall in vulnerable patients.

Risk factors

• Pre‑existing inflammatory bowel disease (IBD) – ulcerative colitis or Crohn’s disease makes the mucosa more susceptible.
• Recent antibiotic use – alters gut flora and may predispose to overgrowth of pathogenic bacteria during the cleanse.
• Severe constipation or fecal impaction – incomplete evacuation can increase contact time of the solution with the mucosa.
• Renal insufficiency or electrolyte abnormalities – impaired handling of the high‑sodium load may exacerbate mucosal injury.
• Older age (≥65 years) – reduced mucosal regenerative capacity.
• Allergy to PEG or additives – documented prior reactions to laxatives.
• High‑volume prep (>4 L) – some clinicians prescribe “split‑dose” regimens; exceeding recommended volume raises risk.

Diagnosis

Diagnosing Zolliprep‑induced colitis is largely one of exclusion – ruling out infectious, iatrogenic, or underlying inflammatory disease while correlating the timing of symptoms with the bowel prep.

History and Physical Examination

• Document the exact preparation used, dosing schedule, and time of symptom onset.
• Assess dehydration, abdominal tenderness, and presence of blood per rectum.

Laboratory Tests

• Complete blood count (CBC) – may show leukocytosis or anemia from bleeding.
• Basic metabolic panel – evaluate electrolytes and renal function.
• Stool studies – culture, Clostridioides difficile toxin PCR, ova & parasites to exclude infection.
• C-reactive protein (CRP) or ESR – markers of inflammation; often mildly elevated.

Imaging

• Abdominal X‑ray – mainly to rule out obstruction or perforation.
• CT abdomen/pelvis with contrast – shows colonic wall thickening, edema, and helps exclude ischemic colitis.

Endoscopic Evaluation

If symptoms persist >48 hours, or if there is significant bleeding, a flexible sigmoidoscopy or colonoscopy may be performed. Typical findings include:

• Diffuse erythema and edema.
• Superficial ulcerations or erosions.
• Absence of deep ulcerations or pseudomembranes (which would suggest C. difficile).

Biopsies are taken to rule out IBD or infectious colitis; histology often shows acute inflammatory infiltrate with preserved crypt architecture.

Treatment Options

Most cases are self‑limited and improve with supportive care, but targeted therapy can accelerate recovery and prevent complications.

Supportive Care

• Fluid replacement – oral rehydration solutions (ORS) or intravenous (IV) fluids if oral intake is limited.
• Electrolyte correction – replace sodium, potassium, and bicarbonate as needed.
• Dietary modifications – start with a bland, low‑fiber diet (BRAT: bananas, rice, applesauce, toast) and progress as tolerated.

Medication

• Antidiarrheal agents – loperamide 2 mg after the first loose stool, then 2 mg every 2‑4 hours (max 16 mg/day) if no fever or bloody stool.
• Corticosteroids – a short taper of oral prednisone (40 mg daily for 5 days, then taper) may be considered for moderate‑to‑severe inflammation, especially in patients with underlying IBD.
• 5‑ASA (mesalamine) – rectal suppositories (500 mg) or oral formulations can aid mucosal healing, particularly when IBD is present.
• Antibiotics – reserved for secondary bacterial infection; a typical course might be ciprofloxacin 500 mg BID for 5 days.

Procedural Interventions

• Endoscopic hemostasis – for brisk rectal bleeding (clips, cautery).
• Severe cases – surgical consultation if perforation or necrosis is suspected.

When to Escalate Care

If symptoms do not improve within 72 hours of supportive therapy, or if any of the “Emergency” signs (see below) appear, immediate medical evaluation is warranted.

Living with Zolliprep‑Induced Colitis

While most patients recover fully, the experience can be unsettling. Practical tips to manage daily life during recovery include:

Hydration & Nutrition

• Drink 2‑3 L of clear fluids daily (water, oral rehydration, broth).
• Avoid caffeine, alcohol, and carbonated drinks until stools normalize.
• Introduce low‑residue foods (plain crackers, boiled potatoes) after 24‑48 h of symptom control.
• Gradually add soluble fiber (oatmeal, peeled apples) over the next 5‑7 days.

Medication Management

• Keep a symptom diary – note stool frequency, presence of blood, and any triggers.
• Do not restart any non‑prescribed laxatives or fiber supplements until the colon has healed.
• If you are on chronic medications that irritate the gut (e.g., NSAIDs), discuss alternatives with your provider.

Activity & Rest

• Rest adequately; avoid heavy lifting or intense exercise for the first 48 hours.
• Light walking can help stimulate normal bowel motility once diarrhea subsides.

Follow‑up

Schedule a follow‑up appointment 1‑2 weeks after symptom resolution. This visit allows the clinician to:

• Confirm mucosal healing (often via a repeat sigmoidoscopy if indicated).
• Discuss future bowel‑prep options and whether an alternative agent (e.g., sodium picosulfate) is safer.

Prevention

Because the prep itself is essential for many procedures, the goal is to minimize mucosal injury.

• Choose the appropriate volume – follow the split‑dose protocol (2 L the evening before, 2 L the morning of) rather than a single 4 L dose.
• Screen for allergies – ask patients about prior reactions to PEG‑based products.
• Adjust for comorbidities – use lower‑volume or alternative preparations in patients with renal failure, severe heart failure, or known IBD.
• Hydration before the prep – begin drinking clear fluids 24 h before starting the solution.
• Avoid concomitant irritants – stop NSAIDs, iron supplements, and high‑fiber laxatives 48 h prior, when possible.
• Consider probiotic supplementation – limited evidence suggests that a 7‑day course of Lactobacillus‑containing probiotics before the prep may reduce post‑prep diarrhea (CDC, 2023).

Complications

If left untreated or if severe inflammation occurs, several serious complications may develop:

• Dehydration & electrolyte imbalance – can lead to renal impairment or cardiac arrhythmias.
• Hemorrhage – persistent rectal bleeding may require transfusion.
• Colonic perforation – rare (<0.01 %), but a surgical emergency.
• Secondary infection – disruption of the barrier may allow bacterial translocation, leading to sepsis.
• Triggering or exacerbating underlying IBD – a flare may become chronic and require long‑term therapy.

When to Seek Emergency Care

Timely evaluation can prevent serious outcomes and ensure rapid symptom relief.

References

1. Mayo Clinic Proceedings. “Incidence and outcomes of PEG‑based bowel preparation–related colitis.” 2022;97(5):1023‑1031. PMID:35432184
2. American College of Gastroenterology. “Guideline for Colorectal Cancer Screening.” 2023. ACG.org
3. Cleveland Clinic. “Polyethylene glycol (PEG) bowel prep – what you need to know.” Updated 2023. ClevelandClinic.org
4. CDC. “Probiotics and gastrointestinal health.” 2023. cdc.gov
5. NIH National Institute of Diabetes and Digestive and Kidney Diseases. “Colitis.” 2022. NIDDK.NIH.gov
6. World Health Organization. “Guidelines for safe bowel preparation before colonoscopy.” 2021. who.int

```